NRF2-mediated ferroptosis suppression defines a cancer-specific vulnerability in tumors
This discovery fundamentally redefines the pathological role of NRF2 and positions NRF2 inhibition as a standalone, tumor-selective therapeutic strategy to eliminate Kras-driven malignancies by unleashing ferroptosis.